Used in the synthesis of pomalidomide derivatives for pharmaceutical research, particularly in developing improved analogs with enhanced efficacy and reduced side effects in treating hematological cancers such as multiple myeloma. Acts as an intermediate in solid-phase and solution-phase synthesis of immunomodulatory compounds. Enables the introduction of functional groups that improve pharmacokinetic properties, solubility, or target binding affinity. Also employed in the development of antibody-drug conjugates (ADCs) by providing a linker attachment point for targeted cancer therapies.